Source comparison
Thymosin Alpha-1 for Post COVID Recovery Research: Comparison
Thymosin Alpha-1 (Tα1) TLR2-mediated dendritic cell activation → T-cell maturation Measurable CD4+ increase by week 4–6 Phase II/III trials with placebo controls $800–$1,200 (research-grade peptide) Strongest immune restoration data in PASC; requires cold stor
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 (Tα1)
- TLR2-mediated dendritic cell activation → T-cell maturation
- Measurable CD4+ increase by week 4–6
- Phase II/III trials with placebo controls
- $800–$1,200 (research-grade peptide)
- Strongest immune restoration data in PASC; requires cold storage and injection compliance
- Intravenous Immunoglobulin (IVIG)
- Passive antibody transfer + immune modulation
- No direct T-cell effect; symptom reduction variable
- Case series and observational studies
- $3,000–$8,000 per infusion cycle
- Used in severe autoimmune presentations; no controlled PASC trials
- Low-Dose Naltrexone (LDN)
- Opioid receptor modulation → reduced neuroinflammation
- Indirect; focuses on symptom management, not immune markers
- Anecdotal reports and small case series
- $30–$60 (compounded oral)
- Accessible and low-risk; lacks immune marker evidence
- Prednisone (Corticosteroid)
- Broad immunosuppression via glucocorticoid receptor
- Suppresses inflammation but worsens T-cell function
- Not studied in PASC recovery context
- $10–$30 (generic oral)
- Contraindicated. Can prolong immune dysfunction